bioclin therapeutics inc logo

BioClin Therapeutics Inc

BioClin Therapeutics is developing monoclonal antibody based drugs against rare genetic orphan disease (achondroplasia/dwarfism) and cancer.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.bioclintherapeutics.com
Founded2010
Disease Focus
Development Stage
STOCK CODENon Listed
Address
130 Market Place, PMB 295,CA 094583
San Ramon
United States
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/bioclin-therapeutics” connections=”true” suffix=””]

In May 2018, BioClin raised an additional $20Mn in funding reaching $50Mn in Series B financing. New investors Sectoral Asset Management and INKEF Capital joined existing investors Sofinnova Ventures, Ysios Capital, HealthCap, Tekla Capital Management funds, and Life Sciences Partners (LSP) in the round. BioClin has raised a total of $79 Mn since its founding.

In 2014, BioClin received $6 Mn USD additional series A funding from Novo A/S Ventures. Earlier in Dec 2012, it received $20 Mn USD from the same investor.